Switching from adalimumab originator to biosimilar: a 3-year retrospective cohort analysis

Clin Exp Dermatol. 2023 Mar 22;48(4):397-398. doi: 10.1093/ced/llac122.

Authors

Lisa Killion¹, Ali Alsharqi^{1

2

3}, Brian Kirby^{1

2

3}

Affiliations

¹ Department of Dermatology, St Vincent's University Hospital, Dublin, Ireland.
² School of Medicine, University College Dublin, Dublin, Ireland.
³ Charles Institute of Dermatology, University College Dublin, Dublin, Ireland.

PMID: 36745550
DOI: 10.1093/ced/llac122

No abstract available

MeSH terms

Adalimumab / adverse effects
Biosimilar Pharmaceuticals* / therapeutic use
Cohort Studies
Humans
Infliximab
Retrospective Studies
Treatment Outcome

Substances

Adalimumab
Biosimilar Pharmaceuticals
Infliximab